Paper6973389
Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil.
Evans RM and 2 others. Cancer Res, 1981. Cited by 342 papers, by iCite.
Cite this record
ConductScience Library. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Papers, record 6973389. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6973389
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fluorouracil | Major topic |
| Inosine | Major topic |
| Leucovorin | Major topic |
| Animals | |
| Carcinoma | |
| Cell Line | |
| Deoxyribonucleosides | |
| Deoxyribose | |
| Deoxyuridine | |
| Drug Synergism | |
| Humans | |
| Mice | |
| Sarcoma, Experimental | |
| Thymidine | |
| Thymidylate Synthase |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA-04175 | NCI NIH HHS | United States | R01CA004175 | PubMed and NIH | NIH RePORTER |
| CA-13038 | NCI NIH HHS | United States | P01CA013038 | PubMed and NIH | NIH RePORTER |
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 342 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42373224 | Analysis of Formimidoyltransferase Cyclodeaminase as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer. | Cancer Genomics Proteomics | 2026 | https://conductscience.org/library/papers/42373224 | PubMed |
| 37206081 | Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. | World J Gastrointest Surg | 2023 | https://conductscience.org/library/papers/37206081 | PubMed |
| 36183444 | A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer. | ESMO Open | 2022 | https://conductscience.org/library/papers/36183444 | PubMed |
| 26189513 | Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. | Invest New Drugs | 2015 | https://conductscience.org/library/papers/26189513 | PubMed |
| 24276379 | Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. | Pharmaceuticals (Basel) | 2013 | https://conductscience.org/library/papers/24276379 | PubMed |
| 16568373 | Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. | J Gastroenterol | 2006 | https://conductscience.org/library/papers/16568373 | PubMed |
| 16222443 | Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study. | Pharm Res | 2005 | https://conductscience.org/library/papers/16222443 | PubMed |
| 15292717 | A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study. | Invest New Drugs | 2004 | https://conductscience.org/library/papers/15292717 | PubMed |
| 15122082 | A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study. | Invest New Drugs | 2004 | https://conductscience.org/library/papers/15122082 | PubMed |
| 14562021 | Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. | Br J Cancer | 2003 | https://conductscience.org/library/papers/14562021 | PubMed |
| 12775023 | Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines. | Gastric Cancer | 2003 | https://conductscience.org/library/papers/12775023 | PubMed |
| 12003195 | Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU). | Invest New Drugs | 2002 | https://conductscience.org/library/papers/12003195 | PubMed |
| 9834413 | Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. | J Gastrointest Surg | 1998 | https://conductscience.org/library/papers/9834413 | PubMed |
| 9045902 | Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3'-azido-3'-deoxythymidine for the gastric cancer cell line MKN28 in vivo. | Jpn J Cancer Res | 1997 | https://conductscience.org/library/papers/9045902 | PubMed |
| 8852401 | How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer. | Med Oncol | 1995 | https://conductscience.org/library/papers/8852401 | PubMed |
| 8690753 | Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats. | J Cancer Res Clin Oncol | 1996 | https://conductscience.org/library/papers/8690753 | PubMed |
| 8369613 | The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo. | Surg Today | 1993 | https://conductscience.org/library/papers/8369613 | PubMed |
| 8198932 | Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. | Br J Clin Pharmacol | 1994 | https://conductscience.org/library/papers/8198932 | PubMed |
| 8174202 | Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8174202 | PubMed |
| 8126062 | Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration. | J Cancer Res Clin Oncol | 1994 | https://conductscience.org/library/papers/8126062 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TYMS | 7298 | PubTator's text mining | https://conductscience.org/library/genes/7298 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6973389
GET https://conductscience.org/api/papers/v1/6973389/cited_by?page=2